- Home
- VIGL vs MPA Comparison
VIGL vs MPA Comparison
Compare VIGL & MPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- MPA
- Stock Information
- Founded
- VIGL 2020
- MPA 1992
- Country
- VIGL United States
- MPA United States
- Employees
- VIGL N/A
- MPA N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- MPA Finance Companies
- Sector
- VIGL Health Care
- MPA Finance
- Exchange
- VIGL Nasdaq
- MPA Nasdaq
- Market Cap
- VIGL 141.5M
- MPA 160.3M
- IPO Year
- VIGL 2022
- MPA N/A
- Fundamental
- Price
- VIGL $3.00
- MPA $12.04
- Analyst Decision
- VIGL Buy
- MPA
- Analyst Count
- VIGL 5
- MPA 0
- Target Price
- VIGL $16.80
- MPA N/A
- AVG Volume (30 Days)
- VIGL 51.3K
- MPA 25.2K
- Earning Date
- VIGL 11-07-2024
- MPA 01-01-0001
- Dividend Yield
- VIGL N/A
- MPA 3.83%
- EPS Growth
- VIGL N/A
- MPA N/A
- EPS
- VIGL N/A
- MPA N/A
- Revenue
- VIGL N/A
- MPA N/A
- Revenue This Year
- VIGL N/A
- MPA N/A
- Revenue Next Year
- VIGL N/A
- MPA N/A
- P/E Ratio
- VIGL N/A
- MPA N/A
- Revenue Growth
- VIGL N/A
- MPA N/A
- 52 Week Low
- VIGL $2.47
- MPA $9.87
- 52 Week High
- VIGL $6.06
- MPA $12.21
- Technical
- Relative Strength Index (RSI)
- VIGL 32.87
- MPA 42.82
- Support Level
- VIGL $2.89
- MPA $12.10
- Resistance Level
- VIGL $3.26
- MPA $12.15
- Average True Range (ATR)
- VIGL 0.22
- MPA 0.13
- MACD
- VIGL -0.08
- MPA 0.01
- Stochastic Oscillator
- VIGL 9.40
- MPA 27.87
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About MPA Blackrock MuniYield Pennsylvania Quality Fund
Blackrock Muniyield Pennsylvania Quality Fund is a closed-end fund with investment objective is to provide shareholders with current income exempt from U.S. federal and Pennsylvania income taxes.